TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial

TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial

Background M6223 is an intravenous (IV), Fc-competent, fully human, antagonistic, anti-T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibody. Bintrafusp alfa (BA) is a bifunctional fusion protein that simultaneously blocks nonredundant...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-02-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/2/e010584.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC
by: Christian Rolfo, MD, PhD, et al.
Published: (2025-01-01)

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies
by: Dean A Lee, et al.
Published: (2023-12-01)

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2024-10-01)

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2025-01-01)

Staphylococcus aureus-specific TIGIT+ Treg are present in the blood of healthy subjects – a hurdle for vaccination?
by: Jonah Clegg, et al.
Published: (2025-02-01)

Experimental investigation of the mechanical properties of Alfas stone
by: Konstas N. Kaklis, et al.
Published: (2017-04-01)

Escalation as a way to resolve conflicts and contradictions
by: J. G. Evdokimova, et al.
Published: (2021-08-01)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Published: (2023-07-01)

Research on coupling evacuation of escalator and staircase in fire scenario.
by: Chunhua Zhang, et al.
Published: (2025-01-01)

Reliability and safety of elevators and escalators/ travelators: Past, present and future
by: Ping Kwan Man, et al.
Published: (2025-03-01)

The role of social isolation stress in escalated aggression in rodent models
by: Aki Takahashi
Published: (2025-02-01)

Climate change and occupational health: Escalating risks and prevention strategies
by: Cyril Cosme
Published: (2025-01-01)

The Beginning and the Reasons of Escalation of the Civil War in Modern Russian Historiography
by: I. V. Mikhailov
Published: (2012-04-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
by: Piotr Kędzierski, et al.
Published: (2025-01-01)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
by: November McGarvey, et al.
Published: (2015-11-01)

Alfa-Fetoprotein-Producing Female Primary Urethral Adenocarcinoma with Neuroendocrine Differentiation
by: Takao Natsuyama, et al.
Published: (2019-01-01)

Escalation to Barbiturate-Induced Coma for Refractory Seizures after Liver Transplantation
by: Brittany Miles, et al.
Published: (2022-01-01)

Vegetation optical depth as a key predictor for fire risk escalation
by: Dinuka Kankanige, et al.
Published: (2025-05-01)

Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells
by: S. González-Ochoa, et al.
Published: (2022-01-01)

The Ratio of CD226 and TIGIT Expression in Tfh and PD-1+ICOS+Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation
by: Ji-wen Fan, et al.
Published: (2022-01-01)

Pokolenie Alfa w szkole. Działania projektowo-wdrożeniowe z wykorzystaniem ICT
by: Eunika Baron-Polańczyk, et al.
Published: (2022-12-01)

The Use of Exogenous Lung Surfactant (Poractant Alfa) in Acute Respiratory Failure by Drowning
by: Mario Pezzi, et al.
Published: (2020-01-01)

Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa
by: Hajime Kato, et al.
Published: (2021-01-01)

Additive Effect of Dornase Alfa and Nacystelyn on Transportability and Viscoelasticity of Cystic Fibrosis Sputum
by: Feng Sun, et al.
Published: (2002-01-01)

QSAR modelling and docking analysis of some thiazole analogues as alfa-glucosidase inhibitors
by: Muhammad Tukur Ibrahim, et al.
Published: (2019-06-01)

Experimental and Numerical Analyses of Alfa/Polyester Composite Under Three-Point Bending
by: Mokhtar Belkacem, et al.
Published: (2025-04-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy
by: Steen Neldam, et al.
Published: (2013-01-01)

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
by: Leonard D’Amico, et al.
Published: (2025-02-01)

Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-03-01)

ALFA e BETO: como avaliar leitura e escrita na Educação Infantil?
by: Magna do Carmo Silva, et al.
Published: (2020-05-01)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010-01-01)

Evaluating a targeted selective speech, language, and communication intervention at scale – Protocol for the Happy Talk cluster randomised controlled trial. [version 3; peer review: 2 approved, 2 approved with reservations]
by: Pauline Frizelle, et al.
Published: (2025-01-01)

NAPTUNE: nucleic acids and protein biomarkers testing via ultra-sensitive nucleases escalation
by: Tao Hu, et al.
Published: (2025-02-01)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
by: Takayuki Ando, et al.
Published: (2015-01-01)

De alfa a omega: Estimación de la confiabilidad ordinal. Una guía práctica
by: Nicolás Vizioli, et al.
Published: (2022-12-01)

Effects of MAPP Compatibilization and Acetylation Treatment Followed by Hydrothermal Aging on Polypropylene Alfa Fiber Composites
by: Noura Hamour, et al.
Published: (2015-01-01)

In the coevolution of cotton and pathogenic fungi, resistant cotton varieties lead to an escalation in the virulence of Verticillium dahliae
by: Yalin Zhang, et al.
Published: (2025-01-01)

Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control
by: Mourad Tighiouart, et al.
Published: (2012-01-01)